+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Rotavirus Infections - Pipeline Review, H1 2020

  • ID: 5024726
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 55 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • Bharat Biotech Ltd
  • GlaxoSmithKline Plc
  • Medicago Inc
  • Micron Biomedical Inc
  • Pfizer Inc
  • UMN Pharma Inc
  • MORE
Rotavirus Infections - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Rotavirus Infections - Pipeline Review, H1 2020, provides an overview of the Rotavirus Infections (Infectious Disease) pipeline landscape.

Rotavirus is a virus that infects the bowels. Rotavirus is the most common cause of severe diarrhea among infants and children. Transmission of rotavirus most often occurs through fecal-oral contact. Usually, this occurs from poor hand washing or from ingestion of contaminated food or water. The virus may also be transmitted through the respiratory tract or by other body fluids, but these routes are less common. The virus may live on inanimate surfaces, such as doorknobs, toys, and hard surfaces. Symptoms may include severe diarrhea, vomiting, fever, and dehydration.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Rotavirus Infections - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Rotavirus Infections (Infectious Disease), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Rotavirus Infections (Infectious Disease) pipeline guide also reviews of key players involved in therapeutic development for Rotavirus Infections and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 2, 2, 1, 5 and 1 respectively. Similarly, the Universities portfolio in Phase III, Phase II, Preclinical, Discovery and Unknown stages comprises 1, 3, 1, 1 and 1 molecules, respectively.

Rotavirus Infections (Infectious Disease) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Rotavirus Infections (Infectious Disease).
  • The pipeline guide reviews pipeline therapeutics for Rotavirus Infections (Infectious Disease) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Rotavirus Infections (Infectious Disease) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Rotavirus Infections (Infectious Disease) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Rotavirus Infections (Infectious Disease)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Rotavirus Infections (Infectious Disease).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Rotavirus Infections (Infectious Disease) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • Bharat Biotech Ltd
  • GlaxoSmithKline Plc
  • Medicago Inc
  • Micron Biomedical Inc
  • Pfizer Inc
  • UMN Pharma Inc
  • MORE
  • Introduction
  • Report Coverage
  • Rotavirus Infections - Overview
  • Rotavirus Infections - Therapeutics Development
  • Pipeline Overview
  • Pipeline by Companies
  • Pipeline by Universities/Institutes
  • Products under Development by Companies
  • Products under Development by Universities/Institutes
  • Rotavirus Infections - Therapeutics Assessment
  • Assessment by Target
  • Assessment by Mechanism of Action
  • Assessment by Route of Administration
  • Assessment by Molecule Type
  • Rotavirus Infections - Companies Involved in Therapeutics Development
  • Aridis Pharmaceuticals Inc
  • Beijing Minhai Biotechnology Co Ltd
  • Bharat Biotech Ltd
  • Chongqing Zhifei Biological Products Co Ltd
  • GlaxoSmithKline Plc
  • Hilleman Laboratories Pvt Ltd
  • Medicago Inc
  • Micron Biomedical Inc
  • Pfizer Inc
  • Serum Institute of India Ltd
  • UMN Pharma Inc
  • Yisheng Biopharma Co Ltd
  • Rotavirus Infections - Drug Profiles
  • (diphtheria + Haemophilus influenza [serotype B] + hepatitis B + pertussis (acellular,adsorbed) + rotavirus + tetanus) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • (rotavirus (virus like particle) + typhiod) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • MDG-5625 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • poliomyelitis vaccine + rotavirus vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Rotavac-5C - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rotavirus (pentavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rotavirus [Serotype P2-VP8] (monovalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rotavirus [Serotype P2] (trivalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rotavirus [serotypes A1, A2, A3, A4] (tetravalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rotavirus [serotypes G1, G2, G3, G4, G9] (pentavalent) vaccine 1 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rotavirus [serotypes G1, G2, G3, G4, P1(8)] (pentavalent) vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rotavirus vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rotavirus vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • rotavirus vaccine - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RV-3BB - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • RV-625 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • UMN-103 - Drug Profile
  • Product Description
  • Mechanism Of Action
  • R&D Progress
  • Rotavirus Infections - Dormant Projects
  • Rotavirus Infections - Product Development Milestones
  • Featured News & Press Releases
  • Jun 03, 2019: Rotavirus vaccine (Rotarix): patient group direction (PGD) template
  • Jan 24, 2018: India-made rotavirus vaccine achieves World Health Organization prequalification
  • Sep 21, 2016: Batavia Biosciences receives grant to develop new vaccine against rotavirus
  • Jun 20, 2013: Medicago Successfully Produces Plant-based Rotavirus VLP Vaccine Candidate
  • Nov 10, 2012: GSK's Rotarix Vaccine To Help Protect Babies Against Rotavirus
  • Apr 26, 2012: GSK’s Rotarix To Be Introduced In Ghana
  • Nov 21, 2011: GSK And Daiichi Sankyo To Launch Rotarix Oral Liquid Formulation To Prevent Rotavirus Gastroenteritis In Japan
  • May 19, 2010: Health Sciences Authority Provides Update On Review Of Presence Of Porcine Circovirus In GSK's Rotarix
  • Oct 15, 1999: Wyeth Lederle Vaccines Voluntarily Withdraws from the Market its Rotavirus Vaccine RotaShield
  • Aug 31, 1998: Wyeth-Ayerst Receives FDA Licensure for RotaShield; First Vaccine for Use in the Prevention of Rotavirus
  • Appendix
  • Methodology
  • Coverage
  • Secondary Research
  • Primary Research
  • Expert Panel Validation
  • Contact Us
  • Disclaimer
List of Tables
  • Number of Products under Development for Rotavirus Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Rotavirus Infections - Pipeline by Aridis Pharmaceuticals Inc, H1 2020
  • Rotavirus Infections - Pipeline by Beijing Minhai Biotechnology Co Ltd, H1 2020
  • Rotavirus Infections - Pipeline by Bharat Biotech Ltd, H1 2020
  • Rotavirus Infections - Pipeline by Chongqing Zhifei Biological Products Co Ltd, H1 2020
  • Rotavirus Infections - Pipeline by GlaxoSmithKline Plc, H1 2020
  • Rotavirus Infections - Pipeline by Hilleman Laboratories Pvt Ltd, H1 2020
  • Rotavirus Infections - Pipeline by Medicago Inc, H1 2020
  • Rotavirus Infections - Pipeline by Micron Biomedical Inc, H1 2020
  • Rotavirus Infections - Pipeline by Pfizer Inc, H1 2020
  • Rotavirus Infections - Pipeline by Serum Institute of India Ltd, H1 2020
  • Rotavirus Infections - Pipeline by UMN Pharma Inc, H1 2020
  • Rotavirus Infections - Pipeline by Yisheng Biopharma Co Ltd, H1 2020
  • Rotavirus Infections - Dormant Projects, H1 2020
List of Figures
  • Number of Products under Development for Rotavirus Infections, H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Universities/Institutes, H1 2020
  • Number of Products by Stage and Targets, H1 2020
  • Number of Products by Stage and Mechanism of Actions, H1 2020
  • Number of Products by Routes of Administration, H1 2020
  • Number of Products by Stage and Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • Aridis Pharmaceuticals Inc
  • Beijing Minhai Biotechnology Co Ltd
  • Bharat Biotech Ltd
  • Chongqing Zhifei Biological Products Co Ltd
  • GlaxoSmithKline Plc
  • Hilleman Laboratories Pvt Ltd
  • Medicago Inc
  • Micron Biomedical Inc
  • Pfizer Inc
  • Serum Institute of India Ltd
  • UMN Pharma Inc
  • Yisheng Biopharma Co Ltd
Note: Product cover images may vary from those shown
Adroll
adroll